Literature DB >> 17517871

Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection.

Mehdi Labaied1, Anke Harupa, Ronald F Dumpit, Isabelle Coppens, Sebastian A Mikolajczak, Stefan H I Kappe.   

Abstract

Malaria infection starts when sporozoites are transmitted to the mammalian host during a mosquito bite. Sporozoites enter the blood circulation, reach the liver, and infect hepatocytes. The formation of a parasitophorous vacuole (PV) establishes their intracellular niche. Recently, two members of the 6-Cys domain protein family, P52 and P36, were each shown to play an important albeit nonessential role in Plasmodium berghei sporozoite infectivity for the rodent host. Here, we generated p52/p36-deficient Plasmodium yoelii parasites by the simultaneous deletion of both genes using a single genetic manipulation. p52/p36-deficient parasites exhibited normal progression through the life cycle during blood-stage infection, transmission to mosquitoes, mosquito-stage development, and sporozoite infection of the salivary glands. p52/p36-deficient sporozoites also showed normal motility and cell traversal activity. However, immunofluorescence analysis and electron microscopic observations revealed that p52/p36-deficient parasites did not form a PV within hepatocytes in vitro and in vivo. The p52/p36-deficient parasites localized as free entities in the host cell cytoplasm or the host cell nucleoplasm and did not develop as liver stages. Consequently, they did not cause blood-stage infections even at high sporozoite inoculation doses. Mice immunized with p52/p36-deficient sporozoites were completely protected against infectious sporozoite challenge. Our results demonstrate for the first time the generation of two-locus gene deletion-attenuated parasites that infect the liver but do not progress to blood-stage infection. The study will critically guide the design of Plasmodium falciparum live attenuated malaria vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517871      PMCID: PMC1951999          DOI: 10.1128/IAI.00225-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Migration of Plasmodium sporozoites through cells before infection.

Authors:  M M Mota; G Pradel; J P Vanderberg; J C Hafalla; U Frevert; R S Nussenzweig; V Nussenzweig; A Rodríguez
Journal:  Science       Date:  2001-01-05       Impact factor: 47.728

2.  P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions.

Authors:  A M Tomas; G Margos; G Dimopoulos; L H van Lin; T F de Koning-Ward; R Sinha; P Lupetti; A L Beetsma; M C Rodriguez; M Karras; A Hager; J Mendoza; G A Butcher; F Kafatos; C J Janse; A P Waters; R E Sinden
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 3.  Plasmodium sporozoite molecular cell biology.

Authors:  Stefan H I Kappe; Carlos A Buscaglia; Victor Nussenzweig
Journal:  Annu Rev Cell Dev Biol       Date:  2004       Impact factor: 13.827

4.  Exploring the transcriptome of the malaria sporozoite stage.

Authors:  S H Kappe; M J Gardner; S M Brown; J Ross; K Matuschewski; J M Ribeiro; J H Adams; J Quackenbush; J Cho; D J Carucci; S L Hoffman; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

Review 5.  A clash to conquer: the malaria parasite liver infection.

Authors:  Sebastian A Mikolajczak; Stefan H Kappe
Journal:  Mol Microbiol       Date:  2006-12       Impact factor: 3.501

6.  A member of a conserved Plasmodium protein family with membrane-attack complex/perforin (MACPF)-like domains localizes to the micronemes of sporozoites.

Authors:  Karine Kaiser; Nelly Camargo; Isabelle Coppens; Joanne M Morrisey; Akhil B Vaidya; Stefan H I Kappe
Journal:  Mol Biochem Parasitol       Date:  2004-01       Impact factor: 1.759

7.  Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes.

Authors:  Jerome P Vanderberg; Ute Frevert
Journal:  Int J Parasitol       Date:  2004-08       Impact factor: 3.981

8.  The infectivity of Plasmodium yoelii in different strains of mice.

Authors:  M Belmonte; T R Jones; M Lu; R Arcilla; T Smalls; A Belmonte; J Rosenbloom; D J Carucci; M Sedegah
Journal:  J Parasitol       Date:  2003-06       Impact factor: 1.276

9.  Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins.

Authors:  Karine Kaiser; Kai Matuschewski; Nelly Camargo; Jessica Ross; Stefan H I Kappe
Journal:  Mol Microbiol       Date:  2004-03       Impact factor: 3.501

10.  Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer.

Authors:  Tomoko Ishino; Kazuhiko Yano; Yasuo Chinzei; Masao Yuda
Journal:  PLoS Biol       Date:  2004-01-20       Impact factor: 8.029

View more
  76 in total

1.  SSP3 is a novel Plasmodium yoelii sporozoite surface protein with a role in gliding motility.

Authors:  Anke Harupa; Brandon K Sack; Viswanathan Lakshmanan; Nadia Arang; Alyse N Douglass; Brian G Oliver; Andrew B Stuart; D Noah Sather; Scott E Lindner; Kevin Hybiske; Motomi Torii; Stefan H I Kappe
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Immunization with genetically attenuated P52-deficient Plasmodium berghei sporozoites induces a long-lasting effector memory CD8+ T cell response in the liver.

Authors:  Bruno Douradinha; Melissa van Dijk; Geert-Jan van Gemert; Shahid M Khan; Chris J Janse; Andy P Waters; Robert W Sauerwein; Adrian Jf Luty; Bruno Silva-Santos; Maria M Mota; Sabrina Epiphanio
Journal:  J Immune Based Ther Vaccines       Date:  2011-10-17

Review 3.  Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one?

Authors:  Bruno Douradinha; Maria M Mota; Adrian J F Luty; Robert W Sauerwein
Journal:  Infect Immun       Date:  2007-12-03       Impact factor: 3.441

Review 4.  Approaches to malaria vaccine development using the retrospectroscope.

Authors:  Vanessa Sardá; David C Kaslow; Kim C Williamson
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

5.  CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii.

Authors:  Katherine L Doll; Noah S Butler; John T Harty
Journal:  Vaccine       Date:  2013-12-07       Impact factor: 3.641

6.  Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites.

Authors:  Olivia C Finney; Gladys J Keitany; Hannah Smithers; Alexis Kaushansky; Stefan Kappe; Ruobing Wang
Journal:  Vaccine       Date:  2014-02-28       Impact factor: 3.641

Review 7.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

9.  Plasmodium yoelii inhibitor of cysteine proteases is exported to exomembrane structures and interacts with yoelipain-2 during asexual blood-stage development.

Authors:  Ying Pei; Jessica L Miller; Scott E Lindner; Ashley M Vaughan; Motomi Torii; Stefan H I Kappe
Journal:  Cell Microbiol       Date:  2013-03-14       Impact factor: 3.715

Review 10.  Malaria: progress, perils, and prospects for eradication.

Authors:  Brian M Greenwood; David A Fidock; Dennis E Kyle; Stefan H I Kappe; Pedro L Alonso; Frank H Collins; Patrick E Duffy
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.